I believe that Coherus BioSciences (CHRS) is a solid buy due to its strategic divestitures aligning the company with an oncology focus, promising clin...
Read More
I believe that Coherus BioSciences (CHRS) is a solid buy due to its strategic divestitures aligning the company with an oncology focus, promising clinical trial results for CHS-114, and the promising momentum observed in the hepatic tumor treatment landscape.